These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25834024)

  • 21. Prescribing bevacizumab off-label contravenes GMC advice.
    Kyle G
    BMJ; 2011 Nov; 343():d7131. PubMed ID: 22077076
    [No Abstract]   [Full Text] [Related]  

  • 22. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
    Lotery A; MacEwen C
    BMJ; 2014 Nov; 349():g6887. PubMed ID: 25406142
    [No Abstract]   [Full Text] [Related]  

  • 23. US ophthalmologists plead with drug regulator not to restrict access to Avastin.
    Cohen D
    BMJ; 2015 Mar; 350():h1266. PubMed ID: 25744537
    [No Abstract]   [Full Text] [Related]  

  • 24. By the way, doctor. My 78-year-old husband has wet macular degeneration. He is being treated with a drug called Avastin. Is that a good choice?
    Heier JS
    Harv Health Lett; 2010 May; 35(7):6. PubMed ID: 20583361
    [No Abstract]   [Full Text] [Related]  

  • 25. [Age-related visual loss].
    Neubauer AS; Kernt M
    MMW Fortschr Med; 2013 Feb; 155(2):36-7. PubMed ID: 23573743
    [No Abstract]   [Full Text] [Related]  

  • 26. Treating age-related macular degeneration: comparing the use of two drugs among medicare and veterans affairs populations.
    Pershing S; Pal Chee C; Asch SM; Baker LC; Boothroyd D; Wagner TH; Bundorf MK
    Health Aff (Millwood); 2015 Feb; 34(2):229-38. PubMed ID: 25646102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-related macular degeneration: treatment at what cost?
    The Lancet
    Lancet; 2018 Sep; 392(10153):1090. PubMed ID: 30303068
    [No Abstract]   [Full Text] [Related]  

  • 28. Minister rules out use of Avastin over Lucentis for wet AMD.
    Kmietowicz Z
    BMJ; 2015 Apr; 350():h2050. PubMed ID: 25882175
    [No Abstract]   [Full Text] [Related]  

  • 29. [Avastin-Lucentis: off-label and surroundings].
    Messori A
    Recenti Prog Med; 2014 Apr; 105(4):137-40. PubMed ID: 24770536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor.
    Giberson M; Taylor V
    Can J Ophthalmol; 2015 Oct; 50(5):393-4. PubMed ID: 26455977
    [No Abstract]   [Full Text] [Related]  

  • 31. The off-label use of medication: the latest on the Avastin - Lucentis debacle.
    Jansen RM
    Med Law; 2013 Mar; 32(1):65-77. PubMed ID: 23781765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survey of Victorian ophthalmologists who use ranibizumab to treat age-related macular degeneration: to identify current practice and modifiable risk factors relevant to post-injection endophthalmitis.
    Buck DA; Dawkins R; Kawasaki R; Sandhu SS; Allen PJ
    Clin Exp Ophthalmol; 2015 Apr; 43(3):277-9. PubMed ID: 25112536
    [No Abstract]   [Full Text] [Related]  

  • 33. [An eye for an eye? Lack of consensus in off-label use of medications leads to major regional differences in medical costs for the treatment of wet AMD in Sweden].
    Bro T
    Lakartidningen; 2017 Nov; 114():. PubMed ID: 29292948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab versus ranibizumab: why are we not playing the joker?
    Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G
    Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322
    [No Abstract]   [Full Text] [Related]  

  • 35. A poke in the eye.
    Gurney M
    Nurs Older People; 2007 Dec; 19(10):3. PubMed ID: 18220056
    [No Abstract]   [Full Text] [Related]  

  • 36. AMD: out of sight out of mind.
    Pountney D
    Nurs Older People; 2007 Dec; 19(10):16-9. PubMed ID: 18220063
    [No Abstract]   [Full Text] [Related]  

  • 37. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
    Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Off with the label and on the Avastin bandwagon: why now and how far?
    Santhan Gopal KS
    Indian J Ophthalmol; 2009; 57(4):253-6. PubMed ID: 19574691
    [No Abstract]   [Full Text] [Related]  

  • 40. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
    Silver J
    JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.